Page 73 - Merck Sharp News Today

/PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer,...

Pembrolizumab plus chemotherapy showed increased efficacy with increasing PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma.

New developments in Australia’s Patent Office and its courts have confirmed that overturning a patent term extension may be the “sleeper” strategy to achieve early generic/biosimilar market entry in Australia.

Clinicians are wondering whether measuring programmed death–ligand 1 (PD-L1) is essential before prescribing checkpoint inhibitors for gastroesophageal cancer.

Concerns over potential conflicts of interest lead to calls for regulator’s policy to be strengthened

Rilzibrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.Additionally, the oral Bruton tyrosine kinase inhibitor demonstrated a low-grade safety profile.

Taipei, April 11 (CNA) Taiwan has signed a second contract with American drugmaker Pfizer to procure 350,000 courses of their COVID-19 treatment medicine Paxlovid, which will arrive by the end of June, Minister of Health and Welfare Chen Shih-chung (陳時中) said Monday.

Adding ipilimumab to pembrolizumab did not improve survival in previously untreated, stage IV non-small cell lung cancer with high PD-L1 expression.

Adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to placebo in patients who had undergone complete resection, according to findings from the phase 3 PEARLS study.

Taipei, April 7 (CNA) Taiwan has plans to procure more of the antiviral COVID-19 drug Paxlovid from Pfizer, according to Minister of Health and Welfare Chen Shih-chung (陳時中) on Thursday.